Objective: In patients with acute myocardial infarction (AMI), estimation of infarct size from the early markers, fatty acid-binding protein (FABP) and myoglobin (MYO), usually assumes average (fixed) rate constants (FCR) for protein clearance from plasma. However, individual variation in FCR is large. Renal dysfunction causes slower clearance of FABP and MYO from plasma and, hence, overestimation of infarct size in 20-25% of patients. We investigated whether or not more accurate values of infarct size could be obtained with individually estimated clearance rates. Methods: Concentrations of FABP and MYO and, for comparison, activities of the established cardiac markers, creatine kinase (CK) and a-hydroxybutyrate dehydrogenase (HBDH), were assayed in serial plasma samples from 138 patients with AMI. Individual FCR values of FABP and MYO were estimated from plasma creatinine concentrations, sex and 21 age. Results: Individual FCR values varied from 0.4 to 2.4 h . Use of these individual FCR values significantly improved the correlation between infarct size, as estimated from FABP or MYO on the one hand, and from CK and HBDH on the other. Approximately equal estimates of infarct size were obtained for all four marker proteins. Conclusions: Using individually estimated clearance rates, renal insufficiency no longer hampers calculation of infarct size from FABP and MYO, and reliable estimates of total myocardial damage can be obtained within 24 h after first symptoms.
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infarction (AMI) [1] [2] [3] [4] . Each of these proteins is abundantly present in the soluble cytoplasm of cardiomyocytes. Due to their small size (15 and 17.8 kDa, respectively), 1. Introduction they are released into plasma in significant amounts within Non-enzymatic cardiac proteins, such as fatty acid-bind-3 h of the onset of AMI, while plasma concentrations ing protein (FABP) and myoglobin (MYO), are increasusually return to normal within 24 h [1] [2] [3] [4] . These characteristics allow early confirmation of AMI, monitoring of coronary recanalisation or reinfarction, and early estima- A drawback of both FABP and MYO, however, is that HBDH, a-Hydroxybutyrate dehydrogenase; CK, Creatine kinase; CK-MB, heart-specific form of CK; Q(t), Cumulative protein release into elimination from plasma takes place mainly by renal plasma from onset of AMI up to time t; GFR, Glomerular filtration rate;
clearance [5] [6] [7] . The influence of renal function on estima- dysfunction, reflected by increased plasma creatinine conthrombolytic therapy after AMI, plasma concentrations of centrations in 25% of patients, infarct size, as estimated FABP and MYO reach peak values within 6 h after the from FABP and MYO, grossly overestimated the values first symptoms and have largely returned to normal after obtained from established cardiac markers such as creatine 12 h (Fig. 2) . Therefore, the adequacy of the sampling kinase (CK) and a-hydroxybutyrate dehydrogenase schedule of the present study for calculation of infarct size (HBDH). Previously, Glatz et al. [9] had found higher from plasma FABP and MYO concentrations could be values for infarct size estimated from plasma FABP than checked as described [9] , using patients who were sampled from HBDH or creatine kinase MB (CK-MB) activity. In hourly up to 12 hours. Reduction of the schedule used in their calculation of infarct size, Glatz et al. [9] as well as the present study caused no systematic effects, but introWodzig et al. [8] used mean (fixed) clearance rates for duced a 15% (SD) scatter in the calculated infarct size. FABP and MYO. However, large deviations from these fixed values may occur, because renal clearance of these 2.2. Analytical techniques small proteins is not only influenced by individual variation in renal function, but also by the age and sex of the Fatty acid-binding protein was measured in duplicate in patient [10, 11] .
plasma samples by a non-competitive enzyme-linked imThe aim of the present study was to establish, in patients munosorbent assay (ELISA), as described elsewhere [14] , with confirmed AMI, if infarct size can be more accurately using an incubation time of 60 min. Samples were diluted determined by using individually estimated clearance rates with phosphate-buffered saline (pH 7.4) containing 0.1% of FABP and MYO, assessed from plasma creatinine bovine serum albumin and 0.05% Tween-20. The detection concentrations, sex and age.
limit of the assay was 0.2 mg / l. Quality control was performed with human plasma, spiked with recombinant human FABP [14] . Intra-and inter-assay imprecision were 2. Methods 4.2 and 9.0%, respectively. Myoglobin was determined in duplicate in plasma by a turbidimetric immunoassay 2.1. Patients and blood sampling (Unimate 3 Myo, art 0751839, Roche, Mijdrecht, The Netherlands) on a Cobas Fara analyzer (Roche Diagnostic Data were obtained from 149 patients with confirmed Systems, Basel, Switzerland). Plasma samples were diluted AMI, enrolled in the GUSTO (Global Utilization of with saline (0.9% NaCl). For quality control, a commercial Streptokinase and t-PA for Occluded Coronary Arteries) standard was used (Roche, art 07 5186). Intra-and interEnzyme Substudy [12] . After obtaining informed consent, assay imprecision were 3.5 and 4%, respectively. Plasma patients received one of four intravenous thrombolytic concentrations of FABP and MYO were expressed in regimens: (1) streptokinase with subcutaneous heparin; (2) mg/l. streptokinase with intravenous heparin; (3) accelerated Activities of CK and HBDH were measured spectrotissue plasminogen activator (t-PA) with intravenous photometrically, in duplicate, at 258C, using a centrifugal heparin or (4) a combination of t-PA and streptokinase, analyser (Cobas Bio System, Roche) and commercially along with intravenous heparin. available test kits (Diagnostica Merck, Darmstadt, GerInclusion criteria for enrolment in the GUSTO study many). The HBDH test is based on the preferential have been described in detail elsewhere [12, 13] . In short, catalytic activity of the myocardial isoforms LDH and 1 patients were eligible when they were admitted to hospital LDH of lactate dehydrogenase in the conversion of a-2 within 6 h after the onset of symptoms, had chest pain ketobutyrate, instead of pyruvate. Activities were exlasting for at least 20 min and showed electrocardiographic pressed in micromoles of substrate converted per minute evidence of AMI ($0.1 mV of ST-segment elevation in and per litre of plasma (U / l). Quality control was pertwo or more limb leads, or $0.2 mV in two or more formed with a commercially available control serum contiguous precordial leads).
(Precipath, Boehringer Mannheim, Germany). Intra-and Blood samples were collected immediately before and 1, inter-assay imprecision were 1.7 and 2.6% for CK, and 2.4 3, 6, 12, 18, 24, 36, 48, 72 and 96 h after the start of and 4.4% for HBDH. thrombolytic therapy, resulting in 11 samples per patient.
Creatinine was analysed on a Beckman Synchron CX-7 The exact sampling time was recorded in the GUSTO system with a commercial test kit (CREA 442760, BeckEnzyme Case Report Form and was expressed as time after man Instruments, Mijdrecht, The Netherlands). The assaý onset of symptoms. Samples were collected in glass tubes is based on a modified Jaffe method, and measures the containing dry heparin, to prevent clotting. After routine change in optical absorbance at 520 nm due to the centrifugation, plasma was kept at 2208C in the local formation of a creatinine-picrate complex in alkaline hospital and was transported in polystyrene boxes with dry solution. Quality control was performed with a control ice to the central laboratory at Maastricht, The Netherserum from the manufacturer, and intra-and inter-assay lands, within eight weeks. Here, samples were stored at imprecisions were 1.3 and 1.9%, respectively. Plasma 2808C until assays were performed. In patients receiving creatinine concentrations, expressed in mmol / l, were mea-sured in the first blood sample, taken at admission, and in Statistical analysis was performed using standard softthe integrals are always evaluated from t 50 up to t 5t.
ware (SPSS). Mean values6SEM were calculated. The Therefore, the true variable is only time t.
non-parametric paired Wilcoxon test was used to test differences between two parameters. Friedman's two-way mmol / l. In a subgroup of 31 patients (26 men and five analyses of variance by ranks (paired) was performed to women), mean plasma creatinine concentrations were test differences between multiple parameters. If the Friedabove the upper reference limit, i.e. 110 mmol / l for men man test indicated a significant (P,0.05) difference, and 97 mmol / l for women, and this group of patients was multiple comparisons were made [20] .
classified as having renal dysfunction. Mean plasma creatinine concentrations in this group were 11865, 13467 and 156610 mmol / l, in the three successive samples, respectively. In the total group of 138 patients, 3. Results the mean calculated glomerular filtration rate was 6161 21 21
(range, 17-104) ml h kg , the mean plasma volume 3. Table 1 .
The gradual rise in creatinine levels, measured at Except for the percentage of women, there were no admission and after 12 and 24 h, indicated that a single significant differences in baseline characteristics and, for measurement at 12 h could probably have been used. further analysis, data from the four treatment groups were Indeed, the ratio of FCR, as calculated from such a single taken together. Due to death, haemolysis, missing samples creatinine value, divided by FCR, as calculated from the and administrative errors, infarct size could not be calcuaveraged value of creatinine, was 1.0260.007, n5136. lated in one, two, seven and ten patients, for FABP, MYO, CK and HBDH, respectively.
Time-concentration curves of marker proteins in 3.2. Plasma creatinine, glomerular filtration rate, plasma and infarct size plasma volume and FCR
Plasma activities and concentrations of the cardiac Average plasma creatinine concentrations at admission, proteins as a function of time are shown in the upper part and 12 and 24 h later were 9462, 9762 and 10464 of Fig. 2 . Peak values were reached 12, 24, 6 and 6 h after mmol / l, respectively. The overall range was 49-337 onset of AMI for CK, HBDH, FABP and MYO, respec- towards the line of identity. In contrast, in patients without High correlations were obtained, and linear regression renal insufficiency, these correlations did not markedly equations approximated the lines of identity. As explained improve by using individual instead of mean FCR values in the Discussion, HBDH was used as the reference protein for FABP and MYO (data not shown). 4. Discussion plasma) and the second term (extravasated protein) in the expression for Q(t) will then both vanish, and infarct size 4.
FCR as a determinant of error in calculated infarct
is simply calculated from the third term by multiplication size of the integral (area under the plasma curve) with FCR. Using fixed mean values for FCR, scatter due to When plasma concentrations of marker proteins in biological variation in FCR will then be fully present in patients with AMI have returned to their normal values, calculated infarct size. This explains why error is relatively 21 extravasated protein has returned to plasma and has also small for HBDH. Due to its slow elimination (1.5% h ), been eliminated. The first term (protein still present in a large part of the released HBDH will still be present in plasma after 72 h (Fig. 2) were shown to correlate well with total glomerular filtralarger variability (40-60%) is found in renal clearance tion rates estimated from creatinine or inulin (5.2 kDa) rates, especially after AMI [16] . This is confirmed in the [10, 11] . Because of their larger molecular sizes, however, filtration starts at a molecular Stokes radius of 2 nm [24] , MYO / FABP concentration ratio in plasma, a measure to whereas the Stokes radius of MYO is 1.9 nm [25] . For discriminate between skeletal and cardiac muscle injury anionic dextrans, however, size-restriction was observed [3] , was rather constant in these patients (5.160.5). Other for a radius of 1.8 nm [26] . As both FABP (pI 5.1) and factors, like hypertension (in 13 out of 31 patients), MYO (pI 7.0) are negatively charged at physiological pH, previously existing kidney dysfunction (creatinine was clearance rates for these proteins could thus be slightly elevated at admission in 19 patients) or diabetes (no lower than those calculated in the present study. This could information available) could have been responsible for explain a slight overestimation of infarct size for FABP renal insufficiency. and MYO, as suggested by Fig. 2 values will generally occur. In hearts from patients who died after AMI, for example, hypertrophy, and variably Of the AMI patients studied, 22% had mean plasma reduced protein content, are common [19, [28] [29] [30] . Such creatinine levels above the upper reference limit and, variability, however, is not observed in the release ratios of hence, were labelled as having renal dysfunction. High different marker proteins. The upper part of Fig. 3 , for plasma creatinine concentrations in these patients could not instance, shows highly correlated release of CK and be explained by previous AMI (in only five of 31 patients), HBDH, with approximately the same ratio as expected the size of the present infarction (r50.04, P50.60), or from healthy myocardium. infarct location (48% anterior and 45% inferior). MoreThis seeming discrepancy has been explained by the over, high plasma creatinine levels could not be caused by phenomenon of 'muscle dilution'. In pathological hearts, additional injury of skeletal muscles because the mean the ratios of cytosolic marker proteins had remained unchanged, in spite of considerable variability in overall injury. In this era of acute reperfusion therapy of AMI, protein content [28] . Apparently, the pathological changes where the emphasis is also on shorter length of stay in could be described by invasion of essentially unaltered hospital, early estimation of infarct size is useful to muscle tissue by non-muscle components, like collagen, fat evaluate the patient's prognosis at an earlier stage, and also or oedema. This implied that estimates of infarct size from to evaluate the effect of therapeutic interventions on infarct different muscle proteins could still be compared, as also size in clinical studies. The present study shows that, using demonstrated in the present study. The term gram equivaindividually estimated clearance rates for FABP and MYO, lent (of healthy myocardium) was adopted [28] to indicate reliable estimates of myocardial infarct size can be obthat one gram equivalent of infarct size could correspond tained within 24 h, while for the established markers CK or to as much as 1.5-2.0 grams of tissue in severely HBDH, a time span of 72 h is required. Moreover, 20-pathological hearts.
25% of patients with elevated creatinine values need no longer be excluded from such measurements, even though 4.5. Concluding remarks and clinical application they may have renal insufficiency. In clinical practice, measurement of creatinine at admission and after 12 and Traditional myocardial marker proteins, like CK, CK-24 h could be reduced to a single measurement after 12 h, MB, LDH (HBDH) and AST, have been shown to be with only minor consequences for the precision of infarct powerful risk markers in patients with AMI, and this was size estimation. recently also demonstrated for the cardiospecific troponins [31, 32] . Compared to these latter proteins, FABP and MYO lack the diagnostic advantage of cardiospecificity, Acknowledgements but have the quantitative advantage of being small cytosolic proteins, rapidly released into circulation and allow-
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